Pancreatic cancer staging treatment pattern. 1.Surgically resectable pancreatic cancer can be considered for 4-8 weeks postoperative with concurrent chemoradiotherapy. 2.Surgeable pancreatic cancer with tumor residual after surgery is recommended to be treated with synchronized chemoradiotherapy for 4-8 weeks after surgery. 3.If the tumor is found to be inoperable or inoperable, intraoperative local irradiation can be considered together with postoperative synchronized chemoradiotherapy. 4.Inoperable resectable locally advanced pancreatic cancer, without jaundice and obvious abnormal liver function, and patients in good physical condition, it is recommended to puncture biopsy and then give synchronized chemoradiotherapy. 5.For locally advanced inoperable patients with jaundice and obvious abnormal liver function, after the bile duct built-in stent or surgery to release jaundice obstruction and improve liver function, synchronized chemoradiotherapy (5-Fu/gicitabine) is recommended if the patient’s physical condition allows it/chemotherapy alone. 6.Patients with local recurrence after surgery, without jaundice and obvious abnormal liver function, and in good physical condition, it is recommended that (5-Fu/gicitabine) synchronized chemoradiotherapy, and those who have biliary obstruction and abnormal liver function, first release the biliary obstruction and improve liver function before considering treatment. 7. When inoperable advanced pancreatic cancer presents with severe abdominal pain, pain caused by metastases in bone or other sites, which seriously affects the patient’s quality of life, synchronized chemoradiotherapy or radiotherapy alone can be considered to reduce the patient’s symptoms and improve the quality of life if the patient’s physical condition allows. For patients with new pancreatic cancer, a complete case and related data file should be established, and regular follow-up and corresponding examination should be performed after treatment. After treatment, patients should be followed up every 3 months within 2 years and every 6 months after 2 years to review blood routine, liver and kidney function, serum tumor markers, abdominal CT/B ultrasound and chest X-ray until 5 years, and then once a year to review blood routine, liver and kidney function, serum tumor markers, abdominal CT/B ultrasound and chest X-ray.